Decoquinate Solid Dispersion via Hot-Melt Extrusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimalarial drugs face challenges such as resistance, high toxicity, and poor bioavailability due to the low water solubility and high lipophilicity of decoquinate, limiting their effectiveness in treating malaria caused by Plasmodium species.
Innovation Solution
A solid dispersion of decoquinate is prepared using hot-melt extrusion technology with a polymeric carrier material and surfactant, which enhances solubility and bioavailability by forming an amorphous state without thermal decomposition, allowing for improved intestinal absorption and pharmacological potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If decoquinate is used as an antimalarial drug, then it shows potent inhibitory and killing effect against Plasmodium, but it has low water solubility and high lipophilicity leading to poor intestinal absorption and low bioavailability
Solution Approach 1:
The patent changes the physical state of decoquinate from crystalline to amorphous by incorporating it into a solid dispersion matrix containing solubility-enhancing excipients. This parameter change in molecular arrangement and solubility characteristics dramatically improves intestinal absorption and bioavailability while preserving the potent anti-malarial efficacy of the drug
Solution Approach 2:
The patent creates a composite material system by formulating decoquinate with solubility-enhancing excipients in a solid dispersion. This composite approach combines the active pharmaceutical ingredient with materials that improve its solubility and dissolution properties, thereby enhancing intestinal absorption without compromising the drug's anti-malarial activity
2Ease of manufacture
If hot-melt extrusion is used to prepare solid dispersion of decoquinate, then solubility and bioavailability are improved, but thermal decomposition may occur at high processing temperatures
Solution Approach 1:
The patent uses solubility-enhancing excipients as intermediary materials that form a protective matrix around the decoquinate molecules during hot-melt extrusion. These excipients lower the processing temperature required and prevent direct thermal exposure of the active ingredient, thereby avoiding decomposition while still achieving the desired solubility enhancement in the final solid dispersion product
3Reliability
If conventional antimalarial drugs like chloroquine and artemisinin are used, then they act during the erythrocyte stage, but they have no inhibitory effects on the parasites at the liver stage and resistance has emerged
Solution Approach 1:
The patent enhances the universality of decoquinate by improving its bioavailability through solid dispersion formulation, enabling it to effectively address multiple stages of the Plasmodium life cycle including both liver stage and erythrocyte stage. This multi-functional capability makes the drug more versatile and effective against various Plasmodium species while reducing the risk of resistance development compared to single-stage antimalarials
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process significantly improves the dissolution rate and bioavailability of decoquinate, leading to enhanced antimalarial efficacy and prolonged circulation in the bloodstream, making it suitable for oral dosage forms like tablets and capsules.
Implementation Method 1
forming an amorphous state without thermal decomposition, allowing for improved intestinal absorption and pharmacological potency
Implementation Method 2
A solid dispersion of decoquinate is prepared using hot-melt extrusion technology with a polymeric carrier material and surfactant
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
The present invention relates to a hot melt extrusion composition, a process for preparing a hot melt extruded product using the hot melt extrusion composition, a solid dispersion of decoquinate, and pharmaceutical uses of the composition and the solid dispersion of decoquinate. The hot melt extrusion composition comprises 5 to 30 % of decoquinate, 60 to 90 % of a polymeric carrier and 0 to 10 % of a surfactant. The hot melt extrusion composition can be melted into a liquid at a temperature below the melting point of decoquinate to achieve complete mixing, effectively avoiding the possible thermal decomposition of decoquinate and other components of the composition during the hot-melt process, thus retaining their original structures and pharmacodynamic activity. In the solid dispersion of decoquinate according to the present invention, the active pharmaceutical ingredient and the formulation excipients are melted into amorphous material with homogeneity, possessing improved solubility and drug releasing rate as well as enhanced oral bioavailability and efficacy.